Establishment of a Protocol for Rapidly Expanding Epstein-Barr-virus-specific Cytotoxic T Cells with Enhanced Cytotoxicity

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2024 Aug 8

PMID 39118069

Authors

Chih-Hao Fang

Ya Fang Cheng

Shian-Ren Lin

Wan-Yu Lai

Li-Ren Liao

Yen-Ling Chiu

Jan-Mou Lee

Affiliations

Soon will be listed here.

Abstract

Background: Lytic Epstein-Barr virus (EBV) infection plays a major role in the pathogenesis of nasopharyngeal carcinoma (NPC). For patients with recurrent or metastatic NPC and resistant to conventional therapies, adoptive cell therapy using EBV-specific cytotoxic T cells (EBV-CTLs) is a promising option. However, the long production period (around 3 to 4 weeks) and low EBV-CTL purity (approximately 40% of total CD8 T cells) in the cell product limits the application of EBV-CTLs in clinics. Thus, this study aimed to establish a protocol for the rapid production of EBV-CTLs.

Methods: By culturing peripheral blood mononuclear cells (PBMCs) from EBV-seropositive donors with EBV-specific peptides and interleukin (IL)-2, IL-15, and interferon α (IFN-α) for 9 days, we identified that IL-15 can enhance IL-2-mediated CTL activation and significantly increase the yield of CTLs.

Results: When IFN-α was used in IL-2/IL-15-mediated CTL production from days 0 to 6, the productivity of EBV-CTLs and EBV-specific cytotoxicity significantly were reinforced relative to EBV-CTLs from IL-2/IL-15 treatment. Additionally, IFN-α-induced production improvement of virus-specific CTLs was not only the case for EBV-CTLs but also for cytomegalovirus-specific CTLs.

Conclusion: We established a novel protocol to rapidly expand highly pure EBV-CTLs from PBMCs, which can produce EBV-CTLs in 9 days and does not require feeder cells during cultivation.

References

Huber J, Farrar J . Regulation of effector and memory T-cell functions by type I interferon. Immunology. 2011; 132(4):466-74. PMC: 3075500. DOI: 10.1111/j.1365-2567.2011.03412.x. View

Pilipow K, Roberto A, Roederer M, Waldmann T, Mavilio D, Lugli E . IL15 and T-cell Stemness in T-cell-Based Cancer Immunotherapy. Cancer Res. 2015; 75(24):5187-5193. PMC: 4681597. DOI: 10.1158/0008-5472.CAN-15-1498. View

Liu Q, Li J, Zheng H, Yang S, Hua Y, Huang N . Adoptive cellular immunotherapy for solid neoplasms beyond CAR-T. Mol Cancer. 2023; 22(1):28. PMC: 9903509. DOI: 10.1186/s12943-023-01735-9. View

Lee J, Hung Y, Chou K, Lee C, Lin S, Tsai Y . Artificial intelligence-based immunoprofiling serves as a potentially predictive biomarker of nivolumab treatment for advanced hepatocellular carcinoma. Front Med (Lausanne). 2022; 9:1008855. PMC: 9679144. DOI: 10.3389/fmed.2022.1008855. View

Choi B, Lee S, Lee M, Kim Y, Kim Y, Ryu K . 4-1BB-based isolation and expansion of CD8+ T cells specific for self-tumor and non-self-tumor antigens for adoptive T-cell therapy. J Immunother. 2014; 37(4):225-36. DOI: 10.1097/CJI.0000000000000027. View

Deshpande P, Cavanagh M, Le Saux S, Singh K, Weyand C, Goronzy J . IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens. J Immunol. 2013; 190(4):1416-23. PMC: 3574821. DOI: 10.4049/jimmunol.1201620. View

Lazarski C, Datar A, Reynolds E, Keller M, Bollard C, Hanley P . Identification of new cytokine combinations for antigen-specific T-cell therapy products via a high-throughput multi-parameter assay. Cytotherapy. 2020; 23(1):65-76. PMC: 7785615. DOI: 10.1016/j.jcyt.2020.08.006. View

Schiavoni G, Mattei F, Gabriele L . Type I Interferons as Stimulators of DC-Mediated Cross-Priming: Impact on Anti-Tumor Response. Front Immunol. 2014; 4:483. PMC: 3872318. DOI: 10.3389/fimmu.2013.00483. View

Hong E, Usiskin I, Bergamaschi C, Hanlon D, Edelson R, Justesen S . Configuration-dependent Presentation of Multivalent IL-15:IL-15Rα Enhances the Antigen-specific T Cell Response and Anti-tumor Immunity. J Biol Chem. 2016; 291(17):8931-50. PMC: 4861462. DOI: 10.1074/jbc.M115.695304. View

10.

Liu Y, Adu-Berchie K, Brockman J, Pezone M, Zhang D, Zhou J . Cytokine conjugation to enhance T cell therapy. Proc Natl Acad Sci U S A. 2022; 120(1):e2213222120. PMC: 9910457. DOI: 10.1073/pnas.2213222120. View

11.

Collin M, Bigley V . Human dendritic cell subsets: an update. Immunology. 2018; 154(1):3-20. PMC: 5904714. DOI: 10.1111/imm.12888. View

12.

Zhang Y, Lyu H, Guo R, Cao X, Feng J, Jin X . Epstein‒Barr virus-associated cellular immunotherapy. Cytotherapy. 2023; 25(9):903-912. DOI: 10.1016/j.jcyt.2023.04.003. View

13.

Pandit H, Valentin A, Angel M, Deleage C, Bergamaschi C, Bear J . Step-dose IL-7 treatment promotes systemic expansion of T cells and alters immune cell landscape in blood and lymph nodes. iScience. 2023; 26(2):105929. PMC: 9852696. DOI: 10.1016/j.isci.2023.105929. View

14.

Mathieu C, Beltra J, Charpentier T, Bourbonnais S, Di Santo J, Lamarre A . IL-2 and IL-15 regulate CD8+ memory T-cell differentiation but are dispensable for protective recall responses. Eur J Immunol. 2015; 45(12):3324-38. DOI: 10.1002/eji.201546000. View

15.

Heslop H, Sharma S, Rooney C . Adoptive T-Cell Therapy for Epstein-Barr Virus-Related Lymphomas. J Clin Oncol. 2021; 39(5):514-524. PMC: 8462582. DOI: 10.1200/JCO.20.01709. View

16.

Xu J, Wei X, Wang Y, Wang F . Current status and advances of immunotherapy in nasopharyngeal carcinoma. Ther Adv Med Oncol. 2022; 14:17588359221096214. PMC: 9083041. DOI: 10.1177/17588359221096214. View

17.

Sumida T, Dulberg S, Schupp J, Lincoln M, Stillwell H, Axisa P . Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells. Nat Immunol. 2022; 23(4):632-642. PMC: 8989655. DOI: 10.1038/s41590-022-01152-y. View

18.

Gary R, Aigner M, Moi S, Schaffer S, Gottmann A, Maas S . Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts. J Transl Med. 2018; 16(1):124. PMC: 5941463. DOI: 10.1186/s12967-018-1498-3. View

19.

Catalina M, Sullivan J, Bak K, Luzuriaga K . Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. J Immunol. 2001; 167(8):4450-7. DOI: 10.4049/jimmunol.167.8.4450. View

20.

Silva-Filho J, Caruso-Neves C, Pinheiro A . IL-4: an important cytokine in determining the fate of T cells. Biophys Rev. 2017; 6(1):111-118. PMC: 5427811. DOI: 10.1007/s12551-013-0133-z. View